[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG10201907291QA - Monomethylfumarate prodrug compositions - Google Patents

Monomethylfumarate prodrug compositions

Info

Publication number
SG10201907291QA
SG10201907291QA SG10201907291QA SG10201907291QA SG10201907291QA SG 10201907291Q A SG10201907291Q A SG 10201907291QA SG 10201907291Q A SG10201907291Q A SG 10201907291QA SG 10201907291Q A SG10201907291Q A SG 10201907291QA SG 10201907291Q A SG10201907291Q A SG 10201907291QA
Authority
SG
Singapore
Prior art keywords
monomethylfumarate
prodrug compositions
compositions
formula
prodrug
Prior art date
Application number
SG10201907291QA
Inventor
David Manser
Hardik Shah
Kristopher Perkin
Ivan Browning
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54066160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201907291Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of SG10201907291QA publication Critical patent/SG10201907291QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

MONOMETHYLFUMARATE PRODRUG COMPOSITIONS The present invention provides pharmaceutical compositions comprising compounds of Formula (I), and methods of treating neurological disorders comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound of Formula (I). 1 10 (I) [No suitable figure] 56
SG10201907291QA 2015-02-08 2015-03-10 Monomethylfumarate prodrug compositions SG10201907291QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562113496P 2015-02-08 2015-02-08

Publications (1)

Publication Number Publication Date
SG10201907291QA true SG10201907291QA (en) 2019-09-27

Family

ID=54066160

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201907291QA SG10201907291QA (en) 2015-02-08 2015-03-10 Monomethylfumarate prodrug compositions
SG11201705124QA SG11201705124QA (en) 2015-02-08 2015-03-10 Monomethylfumarate prodrug compositions
SG10201907289VA SG10201907289VA (en) 2015-02-08 2015-03-10 Monomethylfumarate prodrug compositions

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG11201705124QA SG11201705124QA (en) 2015-02-08 2015-03-10 Monomethylfumarate prodrug compositions
SG10201907289VA SG10201907289VA (en) 2015-02-08 2015-03-10 Monomethylfumarate prodrug compositions

Country Status (24)

Country Link
US (3) US20160228376A1 (en)
EP (1) EP3253377B1 (en)
JP (3) JP2018503651A (en)
KR (1) KR102487136B1 (en)
CN (1) CN107205985A (en)
AU (3) AU2015381240A1 (en)
BR (1) BR112017016378A2 (en)
CA (1) CA2972179C (en)
CY (1) CY1124419T1 (en)
DK (1) DK3253377T3 (en)
EA (1) EA037666B1 (en)
ES (1) ES2879611T3 (en)
HR (1) HRP20211269T1 (en)
HU (1) HUE055210T2 (en)
IL (2) IL252962B (en)
LT (1) LT3253377T (en)
MX (1) MX2017009849A (en)
PL (1) PL3253377T3 (en)
PT (1) PT3253377T (en)
RS (1) RS62186B1 (en)
SG (3) SG10201907291QA (en)
SI (1) SI3253377T1 (en)
UA (1) UA121323C2 (en)
WO (1) WO2016124960A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102675526B1 (en) 2019-01-30 2024-06-14 (주)애거슨바이오 Prodrug compounds of monomethyl fumarate and their pharmaceutical compositions
WO2020198940A1 (en) * 2019-03-29 2020-10-08 深圳仁泰医药科技有限公司 Crystal form a of 2-(2,5-dioxopyrrolidin-1yl)ethylmethylfumarate, preparation method therefor and use thereof
US20220087942A1 (en) * 2019-05-31 2022-03-24 Curacle Co., Ltd. Enteric tablet containing dimethyl fumarate
EP4041218A4 (en) * 2019-09-16 2023-12-27 Glenmark Life Sciences Limited Process for preparation of diroximel fumarate
DE102020104243A1 (en) * 2020-02-18 2021-08-19 Research Center Pharmaceutical Engineering Gmbh Low coherence interferometry on compositions made by thermal fabrication processes
KR102566549B1 (en) * 2021-06-08 2023-08-14 제이투에이치바이오텍 (주) Three-component prodrug, pharmaceutical composition and medical use thereof
WO2022266082A1 (en) * 2021-06-15 2022-12-22 Biogen Ma Inc. Synthetic preparation for diroximel fumarate

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4482547A (en) * 1982-08-26 1984-11-13 Hoechst-Roussel Pharmaceuticals Inc. Substituted-1,3,4-benzotriazepines
DE19721099C2 (en) 1997-05-20 1999-12-02 Fumapharm Ag Muri Use of fumaric acid derivatives
DE19814358C2 (en) 1998-03-31 2002-01-17 Fumapharm Ag Muri Use of alkyl hydrogen fumarates for the treatment of psoriasis, psoriatic arthritis, neurodermatitis and enteritis regionalis Crohn
DE19839566C2 (en) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Use of fumaric acid derivatives in transplant medicine
DE19853487A1 (en) 1998-11-19 2000-05-25 Fumapharm Ag Muri Use of dialkyl fumarate for treating transplant rejection and autoimmune disease
DE10000577A1 (en) 2000-01-10 2001-07-26 Fumapharm Ag Muri Treating mitochondrial diseases, e.g. Parkinson's or Alzheimer's disease or retinitis pigmentosa, using fumaric acid derivative, e.g. mono- or dialkyl fumarate, having succinate dehydrogenase stimulating activity
RS52083B (en) 2001-01-12 2012-06-30 Fumapharm Ag Fumaric acid amides
WO2004082684A1 (en) 2003-03-17 2004-09-30 Acorda Therapeutics Stable oral formulations of aminopyridines and uses thereof
SI1663197T1 (en) 2003-09-09 2008-06-30 Biogen Idec Internat Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
DE10342423A1 (en) 2003-09-13 2005-04-14 Heidland, August, Prof. Dr.med. Dr.h.c. Use of fumaric acid derivatives for the prophylaxis and treatment of genome damage
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
ME02746B (en) * 2004-10-08 2018-01-20 Forward Pharma As Controlled release pharmaceutical compositions comprising a fumaric acid ester
CN101056624A (en) * 2004-10-08 2007-10-17 Adi技术制药股份公司 Controlled release pharmaceutical compositions comprising a fumaric acid ester
WO2006093353A1 (en) * 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited Release-control composition
WO2007042034A1 (en) 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
KR101071516B1 (en) 2006-05-05 2011-10-10 더 리젠츠 오브 더 유니버시티 오브 미시간 Bivalent smac mimetics and the uses thereof
EP3466420A1 (en) 2009-04-29 2019-04-10 Biogen MA Inc. Dimethyl fumarate for the treatment of friedreich ataxia
JP5733930B2 (en) * 2009-09-09 2015-06-10 武田薬品工業株式会社 Solid preparation
EP2811994A4 (en) * 2012-02-07 2016-01-13 Biogen Ma Inc Pharmaceutical compositions containing dimethyl fumarate
CA2882713A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
SG10201707543PA (en) 2013-03-14 2017-11-29 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
US20150307914A9 (en) 2013-08-01 2015-10-29 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
CN104027311A (en) * 2014-05-09 2014-09-10 万特制药(海南)有限公司 Dimethyl fumarate-containing enteric slow-release pellet
MA40985A (en) 2014-11-17 2017-09-26 Biogen Ma Inc MULTIPLE SCLEROSIS TREATMENT METHODS

Also Published As

Publication number Publication date
PT3253377T (en) 2021-07-14
JP2019031550A (en) 2019-02-28
MX2017009849A (en) 2017-12-11
EA201791432A1 (en) 2017-12-29
EA037666B1 (en) 2021-04-28
BR112017016378A2 (en) 2018-03-27
WO2016124960A1 (en) 2016-08-11
KR20170115044A (en) 2017-10-16
CN107205985A (en) 2017-09-26
CY1124419T1 (en) 2022-07-22
AU2015381240A1 (en) 2017-07-06
JP7145918B2 (en) 2022-10-03
IL252962A0 (en) 2017-08-31
LT3253377T (en) 2021-08-25
US20160228376A1 (en) 2016-08-11
CA2972179C (en) 2021-10-26
AU2019200868B2 (en) 2020-05-14
PL3253377T3 (en) 2021-09-27
SI3253377T1 (en) 2021-08-31
IL252962B (en) 2022-07-01
EP3253377B1 (en) 2021-05-12
JP2018503651A (en) 2018-02-08
US20190247315A1 (en) 2019-08-15
ES2879611T3 (en) 2021-11-22
AU2019200868A1 (en) 2019-02-28
IL287830A (en) 2022-01-01
SG10201907289VA (en) 2019-09-27
AU2020205237B2 (en) 2022-04-14
KR102487136B1 (en) 2023-01-10
RS62186B1 (en) 2021-08-31
UA121323C2 (en) 2020-05-12
HUE055210T2 (en) 2021-11-29
US20220257520A1 (en) 2022-08-18
EP3253377A1 (en) 2017-12-13
JP2020203951A (en) 2020-12-24
DK3253377T3 (en) 2021-07-12
HRP20211269T1 (en) 2022-01-21
SG11201705124QA (en) 2017-07-28
CA2972179A1 (en) 2016-08-11
AU2020205237A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
MX2022005290A (en) Heterocyclic compounds as immunomodulators.
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MD4800C1 (en) Aminopyrimidinyl compounds as JAK inhibitors
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MX2019001096A (en) Tlr7/8 antagonists and uses thereof.
SG10201907291QA (en) Monomethylfumarate prodrug compositions
MX368781B (en) Compound inhibiting kinase activities of btk and/or jak3.
MX2020011449A (en) Oxysterols and methods of use thereof.
MX2016010056A (en) 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof.
MX2018003569A (en) C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses.
PH12019500196A1 (en) Compounds and compositions and uses thereof
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
MX2020000523A (en) Isochroman compounds and uses thereof.
PH12016501519A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12018500378B1 (en) Novel annelated phenoxyacetamides
MX2019012522A (en) Therapeutic compounds and methods.
MX2017016231A (en) Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors.
PH12019500822A1 (en) Crystalline forms of eravacycline
MX2019001634A (en) Amide compounds, pharmaceutical compositions thereof, and methods of using the same.
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2017013099A (en) Methods for the treatment of inflammatory disorders.
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
TN2015000524A1 (en) Pharmaceutical compositions